Jeffrey J. Kraws is chief executive officer and co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry (see Awards section). Prior to founding the Company, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co., and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.

Ana Leon Bella is a facilitator in international business negotiations and works as Vice President of International Business development for Crystal Research Associates. She is based in New York City and has worked for international trading companies world-wide. Ana is fluent in several languages including: Spanish, Italian,Chinese, and English. She holds a B.A. in Asian Studies from Cornell University and a M.A. in Dance Education from New York University.  Her combination of language skill and international business experience has proven itself invaluable when integrated with fellow team members at Crystal Research Associates